Pregnancy & Lactation : הריון/הנקה

4.6 Fertility, Pregnancy and lactation
The use of Decitabine Medomie with hormonal contraceptives has not been studied.

Women of childbearing potential/Contraception in men and women
DECITABINE MEDOMIE can cause fetal harm when administered to pregnant women. Due to the genotoxic potential of decitabine (see section 5.3), women of childbearing potential must use effective contraceptive measures and avoid becoming pregnant while being treated with Decitabine Medomie and for 6 months following completion of treatment Men should use effective contraceptive measures and be advised to not father a child while receiving Decitabine Medomie, and for 3 months following completion of treatment (see section 5.3).

Pregnancy
There are no adequate data on the use of Decitabine Medomie in pregnant women. Studies have shown that decitabine is teratogenic in rats and mice (see section 5.3). The potential risk for humans is unknown. Based on results from animal studies and its mechanism of action, Decitabine Medomie should not be used during pregnancy and in women of childbearing potential not using effective contraception. A pregnancy test should be performed on all women of childbearing potential before treatment is started. If Decitabine Medomie is used during pregnancy, or if a patient becomes pregnant while receiving this medicinal product, the patient should be apprised of the potential hazard to the foetus.

Breast-feeding
It is not known whether decitabine or its metabolites are excreted in breast milk. Decitabine Medomie is contraindicated during breast-feeding; therefore, if treatment with this medicine is required, breast-feeding must be discontinued (see section 4.3).

Fertility
No human data on the effect of decitabine on fertility are available. In non-clinical animal studies, decitabine alters male fertility and is mutagenic. Because of the possibility of infertility as a consequence of Decitabine Medomie therapy, men should seek advice on conservation of sperm and female patients of childbearing potential should seek consultation regarding oocyte cryopreservation prior to initiation of treatment with Decitabine Medomie.